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Background: Antibodies (ABs) against the 65-kDa isoform of the intracellular enzyme 
glutamate decarboxylase (GAD65) have been found in limbic encephalitis (LE) and 
other neurological conditions. The direct significance of anti-GAD65-ABs for epilepsy 
is unclear. However, in histological preparations from biopsies of resective epilepsy 
surgeries, predominantly cytotoxic T-lymphocytes were detected making close contacts 
to neurons. Activated T-lymphocytes can, in turn, be selectively controlled by therapeutic 
interleukin-2 receptor Abs, such as basiliximab.
Case presentation: We report of a 25-year-old male patient with epilepsy since the 
age of 18 and displaying clinical signs of LE and a high titer of GAD65 ABs in cerebro-
spinal fluid (CSF) and serum. Monthly, repetitive, intravenous cortisone pulse therapies 
that were initially administered for 6 months failed to improve his condition. Subsequent 
flow-cytometry analysis of CSF showed especially an increased fraction of activated 
HLA-DR+ CD8+ T-lymphocytes (fCD8+TL) when compared to controls. Thus, a second, 
intravenous cortisone pulse therapy with an additional basiliximab dose of 20 mg/month 
was started. After 3 months, the fCD8+TL in the CSF normalized; after 6 months, the 
psychological impulse-control deficits normalized; and after 11  months the patient 
was seizure free. However, 7 weeks later, seizures and, later on, psychological deficits 
recurred and fCD8+TL was once again present in the CSF. Flumazenil PET, magnetic 
resonance imaging-volumetry, and neuropsychological changes during therapy are 
described.
Conclusion: The correlation of the fCD8+TL in the CSF with clinical and paraclinical 
measures of disease activity combined with the unambiguous response to basiliximab 
strongly argues in favor of the putative pathogenic role fCD8+TL in anti-GAD65 LE. The 
clinical relapse at the end of the observation period might be due to the formation of 
human anti-drug ABs, a well-known complication of therapy with chimeric ABs.
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introduction
In 2009, a male patient with temporal lobe epilepsy (TLE) that 
started at the age of 18 was admitted to the Department of 
Epileptology, University of Bonn, 2  years after his initial diag-
nosis. He displayed some clinical signs compatible with limbic 
encephalitis (LE): seizures of temporal semiology starting in 
adult age but lasting no longer than 5 years, as well as affective 
disturbances with prominent mood lability, or disinhibition (1, 
2). Since symptomatic, anticonvulsant therapy failed to control 
his seizures, the patient was assessed in 2011 to ascertain whether 
or not he was a suitable candidate for epilepsy surgery. Brain 
magnetic resonance imaging (MRI) revealed distinct signs 
of temporomesial encephalitis [T2/fluid attenuated inversion 
recovery (FLAIR): distinct hyperintensity without atrophy, see 
Figure  1A]. A 2-fluoro-2-desoxy-d-glucose positron emission 
tomography (FDG-PET) displayed a bitemporal (right >  left), 
hypometabolism (see Figure  1B). Neuropsychological tests 
[EpiTrack® (3), VLMT (4), and DCS-R (5)] revealed deficits in 
frontal and right temporal functions. During scalp video-EEG 
monitoring, three habitual seizures were recorded: two seizures 
originated from the left temporal region and one seizure from 
the right frontotemporal region (see Figure 1C). Because of the 
bilateral seizure onset and the lack of a clear epileptogenic lesion 
in the MRI (e.g., unilateral hippocampal sclerosis), the presurgi-
cal evaluation was discontinued. Furthermore, complementary 
investigations including the search for autoantibodies against 
neuronal antigens in the serum and later on cerebrospinal fluid 
(CSF) were performed (Euroimmun AG, Lübeck, Germany): the 
serum was tested for BIOCHIP-Mosaic immunofluorescence 
Anti-Hu, -Ri, -Yo, -Tr, -MAG, -Myelin, -Ma/Ta, -Amphiphysin, 
-CV-2, -Aquaphorin-4, -Glycinereceptors, -GAD (65  kDa); 
IgAGM IFT Anti-NMDA, -AMPA, -GABA-b receptors; IgAGM 
IFT Anti-LGI1, -CASPR2; Anti GAD (65 kDa) IgG ELISA, Anti 
potassium-channels RIA.
A high concentration of glutamic acid decarboxylase (65 kDa)-
antibodies (GAD65-ABs) was found in serum (>2000 IU, ELISA; 
1:1000 BIOCHIP-Mosaic immunofluorescence) and later on in 
the CSF (Biochip immunofluorescence++ 1:10), leading to the 
final diagnosis of a GAD65-AB positive LE. All other tests for 
FiGuRe 1 | (a) Brain magnetic resonance imaging (MRI), T2/fluid attenuated 
inversion recovery (FLAIR) showing a distinct bilateral temporomesial 
hyperintensity without atrophy. (B) 2-fluoro-2-desoxy-d-glucose positron 
emission tomography (FDG-PET) showing a bitemporal (right > left), 
hypometabolism. Both images were scanned before therapy, in November 
2011. (C) EEG of two seizures. One second per line. Left: seizure starting with 
atypical sharp-slow-wave complex and irregular theta activity left temporal. 
Clinical start 11 s later with eye opening, oral automatisms, leg movements, 
later on secondary generalization. Right: seizure starting with irregular delta 
activity right frontotemporal with fast transition to left frontal contacts. Clinical 
start 34 s later with eye opening, non-verbal vocalization, sitting up, staring, 
later on secondary generalization.
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competing causes of mediotemporal encephalitis were normal. 
Importantly, other conditions associated with GAD65 ABs (such 
as type 1 diabetes mellitus) were absent in our patient.
During the patient’s in-hospital stay, a postictal episode with 
acute physical aggression occurred. Later on, repeated episodes 
of seizure independent, inappropriate behavior with physical 
and verbal aggression were observed. Finally, the patient started 
arguing with another fellow patient about his supposed loud talk-
ing, which later resulted in a violent assault. Consequently, the 
patient was then transferred to a locked psychiatric ward and an 
antipsychotic therapy with risperidone was started.
Additionally, a cortisone pulse therapy with a monthly appli-
cation of 1  g/day methylprednisolone (Urbason®, Sanofi) over 
5 days was administered for 6 months. This therapy, however, did 
not change his disease in any way. The time course of the disease 
can be seen in Table 1.
The subject of this case report is the second immunomodula-
tory therapy comprising a cortisone pulse therapy with monthly 
applications of 1  g/day methylprednisolone (Urbason®, Sanofi) 
over 5 days and 20 mg basiliximab monthly applied on day 3 of the 
cortisone pulse therapy. The therapy was continued for 6 months 
under nearly constant anticonvulsant medication and, because 
of initial improvements, his therapy was extended to 14 months. 
However, during the extension period, the anticonvulsant medi-
cation was changed due to side effects and the cortisone pulse 
therapy was shortened to 3 days, with an application of 20 mg 
basiliximab on day 2.
Background
Limbic encephalitis is an autoimmune encephalitis with medi-
otemporal lobe symptoms caused by inflammatory lesions in 
limbic structures, which leads to a TLE, impairment of recent 
memory, and affective disturbances, which have mostly been 
observed in adults. Initially, LE was thought to mainly occur 
as a paraneoplastic symptom. However, it can also occur as a 
non-paraneoplastic disease (2). LE is subclassified according to 
the presence of autoantibodies against either neuronal surface 
antigens or intracellular targets (6). In a series of nine patients 
with LE symptoms and high titer GAD65 ABs, none of the seven 
patients who received intravenous Methylprednisolone pulses 
(500–1000 mg/day on three to five consecutive days) for up to 
6 months became seizure free about 12 months after their initial 
assessment (1). Therapy was even escalated in some cases and a 
high dosage of intravenous immunoglobulin or cyclophospha-
mide was administered. However, these interventions resulted in 
the concentration of ABs being reduced to only 57% (69–3%) of 
the initial concentration.
The histopathology, which was available, revealed that 
T-lymphocytes, in particular, were found in patients with 
GAD65-AB LE (1, 7).
A possible therapy aimed at reducing the amount of activated 
T-lymphocytes can be initiated by using therapeutic ABs against 
the activated interleukin-2 receptor (8). Up until that point in 
time, only basiliximab (Simulect®, Novartis International AG) 
was available. Basiliximab is a chimeric, mouse-human mono-
clonal AB to the α chain (CD25) of the interleukin-2 receptor 
of T-lymphocytes. It was approved in 1998 to prevent rejection 
in organ transplantation, especially in kidney transplants. In this 
case, it was given as an individual treatment attempt after written 
informed consent was obtained. The therapy included monthly 
intravenous applications of 20 mg basiliximab. Since basiliximab 
is a chimeric AB, which carries a significant risk for the develop-
ment of anaphylactic reactions due to human anti-drug antibod-
ies (HADAs), (9–11) and also because it is recommended that 
basiliximab be combined with additional immunotherapies (12), 
an additional cortisone pulse therapy with monthly applications 
of 1 g Methylprednisolone (Urbason®) per day over 5 days was 
applied. Basiliximab was given on day 3 of the cortisone pulse 
therapy in order to achieve maximum protection against anaphy-
lactic reactions due to HADAs. As described above, the therapy 
was continued for 6 months and, because of initial improvements, 
it was then extended to 14 months. During the extension period, 
the anticonvulsant medication had to be changed due to side 
effects and the cortisone pulse therapy was shortened to 3 days, 
with an application of 20 mg basiliximab on day 2.
Results
In the presented case, GAD65-ABs were above the limit of 2000 IU 
before, during, and after initial Cortisone pulse therapy in the 
peripheral blood (PB). In the CSF, GAD65-ABs were also found 
during and after cortisone pulse therapy. The first examination 
of CSF did not occur prior to the start of cortisone pulse therapy, 
since hospitalization was abruptly terminated by transferring the 
patient to a locked psychiatric ward.
In order to evaluate whether or not there are predominantly 
activated T-lymphocytes in the central nervous system in this 
patient, like histopathological findings showed in former patients 
with GAD65-AB LE, flow-cytometry analysis of PB and CSF was 
performed using a 10 color panel (Figure 2, “baseline,” see also 
Changes in the CSF Using Flow Cytometry and Antibody Tests) 
in order to differentiate granulocytes, monocytes, NK-cells, NKT 
cells, B-lymphocytes (plasma-cells), and T-lymphocytes (CD4/
CD8 and the stimulation-marker HLA-DR) (13). Results were 
compared with 24 controls (emergency-patients, mostly with 
severe headache, but ultimately without evidence for meningitis 
or subarachnoid bleeding, see Figure 3 “baseline”). As compared 
to normal controls, the fraction of activated CD4+ as well as CD8+ 
T-lymphocytes was significantly increased (by more than 2 SDs) 
in the CSF.
In order to monitor the course of disease during therapy, 
repeated neuropsychological tests, MRI volumetry, measures 
of AB-titers, and seizure counts were performed. GAD65 is an 
enzyme that catalyzes the decarboxylation of glutamic acid to 
gamma-aminobutyric acid (GABA). It can be expected that if this 
disease implies a dysfunction of GABAergic neurons, it might 
also reduce the amount of available GABA in the brain and there-
fore increase the number of GABA-receptors. This should result 
in more (GABAA) binding sites, e.g., for 11C-flumazenil PET. 
Therefore, before and after 6 months of therapy, an 11C-flumazenil 
PET was performed in order to achieve an additional biomarker 
to evaluate if a specific effect existed, which justified a continua-
tion of the therapy.
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12.01.07 I/e GTC: 1/m Initially PHT 200/d + LTG,  
later: LEV 500-0-1000  
LTG 200-0-250
Escitalopram 
10-0-0
Opipramol 
50-0-0
20.10.09 O Seizure free 
3 m
LEV 1000-0-1000 LTG 
100-0-100
Escitalopram 
20-0-0
Theta left 
temporal
18.09.10 O/e CPS 1/m LEV 2000-0-2000 LTG 
100-0-100
Escitalopram 
20-0-0
Normal
31.03.11 O/e CPS 1/m LTG 100-0-100 Theta 
bi-temporal 
l > r
11.04.11 I/e GTC-series LTG 150-0-150 Theta 
bi-temporal 
l > r 
23.05.11 I/e GTC-series LTG 200-0-200, VPA 300- 
0-300 LEV 500-0-500
Diffuse  
slowing
25.08.11 I/e 3-4 CPS/m LTG 200-0-200, VPA 300- 
0-300 LEV 500-0-500
09.09.11 O 10 CPS/m LEV 1000-0-1000 LTG 
200-0-200
24.11.11 I 2 CPS/m LTG 200-0-200, OXC 600- 
0-600 PGB 0-0-75
Olanzapine 
0-0-2.5
TIRDA l > r, 
SSW in sleep
FDG-PET >2000 n.d.
1 GTC/m
14.12.11
5 
d/
m
on
th
, 6
 m
on
th
s
I/e 2 CPS/m LTG 200-0-200, OXC 600- 
0-600 PGB 0-0-75
Risperidone 
1-0-01 GTC/m
19.12.11 O 2 CPS/m LTG 200-0-200, OXC 600- 
0-900 PGB 0-0-75
Risperidone 
1-0-01 GTC/m
08.02.12 I 3 CPS/m LTG 200-0-200, OXC 600- 
0-600 PGB 0-0-75
Risperidone 
1-0-0
>2000 
1:1000
1:10 IgG
1 GTC/m
14.07.12 I 2 CPS/m LTG 200-0-200, OXC 600- 
0-600 PGB 0-0-75
Risperidone 
1-0-0
SSW r. 
temporal
>2000 
1:10001 GTC/m
13.03.13 O 2 CPS/m LTG 200-0-200 OXC 750- 
0-750 PGB 150-0-150
Risperidone 
1-0-01 GTC/m
11.04.13 I 2 CPS/m LTG 150-0-150 OXC 
600-600-600 
Risperidone 
1-0-0
SSW r. 
temporal
>2000 
1:10001 GTC/m
11.05.13 O/e 2–3 CPS/m LTG 100-100-100 OXC 600-
600-600 ZON 200-0-200
Risperidone 
1-0-01 GTC/m
01.08.13 #1 5 d I 2–3 CPS/m LTG 100-100-100 OXC 600-
600-600 ZON 200-0-200
Risperidone 
0.5-0-0
Flumazenil 
PET #1
>2000 
1:320
1:3.2 – Before 
therapy1 GTC/m
03.09.13   I/e LTG 100-100-100 OXC 600-
600-600 ZON  
paused
Risperidone 
0.5-0-0
renal failure 
17.09.13 #2 5 d I CPS 3/m LTG 100-100-150, OXC 600-
600-600 ZON 200-0-200
Risperidone 
0.5-0-0
SSW r. 
temporal
31.10.13 #3 5 d I CPS 5/m LTG 100-100-150, OXC 600-
600-600 ZON 200-0-200
Risperidone 
0.5-0-0
n.d. 1:100 Neg. – After 
therapy
12.11.13 – O/e LTG 100-100-150, OXC 600-
600-600 ZON 200-0-200
Risperidone 
0.5-0-0
bitemporal 
slowing l > r
09.12.13 #4 5 d I CPS 3/m LTG 100-100-150, OXC 600-
600-900 ZON 200-0-200
Risperidone 
0.5-0-0
SSW r. 
temporal
n.d. 1:1000
(Continued)
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24.01.14 #5 5 d I 7 CPS/m LTG 100-100-150, OXC 600-
600-900 ZON 200-0-200
Risperidone 
0.5-0-0
FDG-PET
2 GTC/m
12.03.14 #6 5 d I CPS 3/m 
(only nightly, 
shorter)
LTG 100-100-150, OXC 600-
600-900 ZON:weight-loss
Risperidone 
0.5-0-0
SSW 
bi-temporal 
r >> l
Flumazenil 
PET #2
n.d. 1:320 Neg. – Before 
therapy
19.04.14 #7 3 d I CPS 2/m 
(only nightly, 
shorter)
LTG 100-100-150, OXC  
600-600-900 weight-gain after 
removal of ZON
Risperidone 
stopped
30.05.14 #8 3 d I 7 CPS/m LTG 100-100-150, OXC 600-
600-900 PER 0-0-21 GTC/m
14.07.14 #9 3 d I CPS 3/m LTG 100-100-150, OXC 600-
600-900 PER 0-0-8
15.08.14 #10 3 d I CPS 3/m LTG 100-100-150, OXC 600-
600-900 PER 0-0-10
10.09.14 #11 3 d I CPS 1/m LTG 100-100-150, OXC 600-
600-900 PER 0-0-10
27.10.14 #12 3 d I No seizures LTG 100-100-150, OXC 600-
600-900 PER 0-0-10
n.d. 1:1000
06.12.14 #13 3 d I CPS 3/m 
(7 weeks 
seizure free)
LTG 100-100-150, OXC 600-
600-900 PER 0-0-10
19.01.15 #14 3 d I CPS 3/m LTG 100-100-150, OXC 600-
600-900 PER 0-0-10
n.d. 1:1000 1:1 – After 
therapy
I, inpatient; O, outpatient; /e, external hospital; d, days; CPS, complex partial seizures; GTC, generalized tonic clonic seizures; m, month; PHT, phenytoin; LTG, lamotrigine; VPA, 
valproate; LEV, levetiracetam; OXC, oxcarbazepine; ZON, zonisamide; PER, perampanel; r, right; l, left; TIRDA, temporal intermittent rhythmic delta activity; SSW, sharp-slow-waves; 
n.d., not done.
taBle 1 | Continued
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Changes in the CsF using Flow Cytometry and 
antibody tests
Cells derived from the PB and the CSF of the patient with GAD65-
AB-associated autoimmune encephalitis at baseline, after the 3rd 
dose, before the 6th dose, and after the 14th dose of basiliximab 
were analyzed using the flow cytometry, as described in Figure 2.
The percentage of activated cytotoxic T-lymphocytes 
(HLA-DR+ CD8+) and T-helper cells (HLA-DR+ CD4+) was 
compared with 24 controls (emergency patients, mostly with 
severe headache, but ultimately without evidence for meningitis 
or subarachnoid bleeding, see Figure 3): before therapy, the frac-
tion of activated CD4+ as well as CD8+ T-lymphocytes was sig-
nificantly increased (more than 2 SDs) in this patient’s CSF. After 
the third application of basiliximab, both parameters were within 
normal limits and remained there prior to the sixth application. 
GAD65-ABs were no longer detectable in the CSF after the third 
and before the sixth application of basiliximab, in contrast to the 
time before treatment (Table 1). A last measurement was made 
after the 14th application, about 2 months after seizures recurred. 
In the two-dimensional plot, the measurement of percentage of 
activated CD4+ and CD8+ T-lymphocytes marginally crosses the 
border of 2 SDs and is once again outside the normal range. In 
undiluted CSF, the immunofluorescence test for GAD65-AB was 
positive again.
In CSF, predominantly T-lymphocytes, but only a few 
B-cells and no plasma cells, can be found. The fraction of 
B-cells (% of all lymphocytes) was between 0.7 and 1.81% and 
thus always within normal limits (mean: 0.92%; SD: ±0.83%).
The absolute number of leukocytes in the CSF was always 
within normal limits. Oligoclonal bands, IgG, just in CSF, 
were only positive at the first CSF analysis during the first 
cortisone pulse therapy.
Changes in neuropsychology, Behavior, and 
eeG
As demonstrated in Figure 4, the initial assessment (07.11.2011) 
showed deficits in executive functions and figural memory, which 
is indicative of frontal and right temporal dysfunction. The intro-
duction of neuroleptic treatment, and adjunctive antiepileptic 
treatment with oxcarbazepine plus immunotherapy with meth-
ylprednisolone, was accompanied by significant deterioration in 
verbal and figural memory and executive function (second assess-
ment: 07.02.2012). Within the next 5  months, verbal memory 
showed further significant decline, while figural memory and 
executive functions remained at the low-performance level (third 
assessment: 12.07.2012). About 9 months after the first 6-month 
cycle of Methylprednisolone (fourth assessment: 04.11.2013), 
verbal memory was found to be significantly improved and within 
FiGuRe 2 | Gating strategy of flow-cytometry (13). Cells from peripheral 
blood (PB) and cerebrospinal fluid (CSF) at baseline, after 3rd dose, before 
6th dose, and after 14th dose of basiliximab were stained using fluorochrome 
labeled antibodies directed against the linage markers CD45 (leukocytes), 
CD14 (monocytes), CD19 (B cells), CD138 (CD19lowCD138+ plasma cells), 
CD3 (T cells), CD56 (NK cells), CD4 (CD4+ T cells), and CD8 (CD8+ T cells) 
and the activation marker HLA-DR and analyzed by multicolor flow cytometry. 
CD45+ leukocytes were selected in a CD45-KromeOrange versus forward 
scatter (FSC) plot. CD45+ cells were then displayed in a CD14-FITC versus 
sideward scatter (SSC) plot and CD14− lymphocytes were selected. (a) 
Lymphocytes were displayed (CD138-PE/CD19-A700) and CD19+CD138− B 
cells or CD19lowCD138+ plasma cells were selected. (B) Lymphocytes were 
displayed (CD3-PC5.5/CD56-PC7 plot) and CD3+CD56− T-cells were 
selected. T-cells were split into CD4+ and CD8+ subsets in a CD4-APC 
CD8-PacificBlue plot. (C,d) The percentage of HLA-DR positive CD4+  
T-cells (C) and CD8+ T-cells (d) was analyzed including 
CD45+CD3+CD56−CD4+CD8− and CD45+CD3+CD56−CD4−CD8+ 
lymphocytes, respectively.
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the normal range, whereas figural memory and executive function 
remained unchanged. At the fifth assessment (25.07.2013) – after 
uptitration of Zonisamide as third concurrent antiepileptic 
agent  –  a general decline in all three cognitive domains (but 
especially in verbal memory) was observed. This fifth assessment 
also represented the baseline before introduction of basiliximab. 
The final neuropsychological evaluation (sixth assessment: 
05.03.2014) after five cycles of basiliximab in combination with 
methylprednisolone revealed a steady decrease in executive 
function and again a significant decline in verbal memory. At 
this final follow-up, memory performance measured more than 3 
SDs below the mean of the normative sample of healthy controls, 
while executive functions were more than 2 SDs below normal.
At disease onset, significant mood disorders and psychic dis-
inhibition occurred simultaneously, with aggressive outbursts and 
physical violence, as described above. These changes diminished 
during therapy. As described in Table 1, the neuroleptic therapy 
with risperidone was discontinued under immunomodulatory 
therapy. However, risperidone was reduced from a daily dose of 
2 mg down to 0.5 mg before therapy onset. The last contact with the 
patient took place 3 months after treatment ended, and he displayed 
significant affective disorders and psychic disinhibition again.
The visual EEG-analysis reported in Table 1 mostly revealed 
bitemporal alterations and did not show any obvious changes. 
Initially, there is a transition of main temporal focus from left 
to right that might coincide with volume changes in MRI (see 
MRI-Volumetry). In general, EEG-related biomarkers for LE are 
still missing.
Flumazenil Pet
Before the first application and after the sixth application of basi-
liximab, an 11C-flumazenil PET (14) was performed at the nuclear 
research center in Jülich. Injected activity for the first scan was 580 
and 674 MBq for the second scan. Data were normalized to the 
injected activity in order to compare both scans. Furthermore, 
the acquisition time was kept constant by starting the acquisition 
20 min after the injection and stopping 40 min after the injec-
tion. Results are shown in Figure 5. Flumazenil uptake is reduced 
under therapy with basiliximab. Since flumazenil binds to GABAA 
receptors, these findings can be interpreted as a reduction of 
FiGuRe 3 | Fraction of activated (=Hla-dR+) Cd8+ and Cd4+ 
t-lymphocytes of the patient at baseline, after 3rd, before 6th, and 
after 14th application of basiliximab (red dots), compared with 
normal controls (blue dots). Only data from CSF are shown. The center 
of the blue ellipse is the mean of normal controls; the major axis of the 
ellipse represents mean plus/minus 2 SDs of the fraction of activated 
CD8+ T-lymphocytes; the minor axis of the ellipse represents mean plus/
minus 2 SDs of the fraction of activated CD4+ T-lymphocytes of normal 
controls. Thus, dots outside of this ellipse significantly differ from normal 
controls.
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GABAA-receptors under therapy, which might be a consequence 
of a better GABA – supply. Since GABAergic neurons contain glu-
tamate decarboxylase enzymes (GAD, e.g., GAD65) to produce 
their transmitter, the observed reduction of GABA-receptors 
could be interpreted as a recovery of GABAergic neurons, thus 
implying preceding functional impairment by cytotoxic T-cells.
Changes in seizure Frequency
The seizure frequency before and during therapy was counted 
from the patient’s diary and is shown in Table 1. After 6 months, 
the seizure situation improved slightly: the duration became 
shorter and seizures occurred only at night. Since the anticonvul-
sant medication was kept constant for this period, these improve-
ments could be attributed to the immune modulatory therapy. 
However, the patient’s significant weight-loss resulted in the deci-
sion to taper down Zonisamide. At the same time, the duration of 
the cortisone pulse therapy was reduced from 5 to 3 days. After 
these interventions, the number of seizures increased, as did their 
severity. The new anticonvulsant drug perampanel was given as 
an add-on. One month after reaching a constant daily dose of 
10 mg, the seizures stopped for about 7 weeks. It remains unclear 
if this is the result of the long-lasting therapy with basiliximab or a 
success of the recently approved anticonvulsant drug perampanel, 
or perhaps a result of both. However, after stopping the immune 
modulatory therapy, even more seizures occurred (up to 5 GTC 
seizures per month, not shown in Table 1) and ultimately resulted 
in further changes regarding the choice of anticonvulsant drugs.
MRi-Volumetry
Between November 2011 and October 2014, a total of 11, 3-T 
MRI examinations were performed on the patient. Since it was 
difficult to schedule the investigations using only one MRI scan-
ner, the investigations were performed either on a Siemens Trio 
(six times) or with a Philips Achieva Scanner, using a similar 
protocol. Volumetric analysis was performed on the comparable 
3D, 1 mm3 isotropic voxels, MPR-T1-weighted image from each 
scanner. All image processing was implemented with the software 
FSL (Version 5.0.4, FMRIB Analysis Group, University of Oxford, 
England) (15). The analysis comprises whole brain segmentation 
(16) used to calculate the total brain volume, and subcortical 
segmentations of hippocampi and amygdala (17). As is usual in 
volumetric studies, raw measurements were corrected by the total 
brain volume, which aims to eliminate the variability between 
the two scanners. As seen in Figure 6, some fluctuations in the 
relative volume of right and left hippocampi and amygdalae were 
present throughout the observation period, which might coincide 
with a transition of main interictal temporal EEG-focus from left 
to right (Table 1). On the other hand, the volume of both amyg-
dalae shows a noticeable reduction at the end of the observation 
period, when the patient was seizure free (Table 1).
General side effects
About 2 weeks after the first application of basiliximab and meth-
ylprednisolone, the patient experienced renal failure for unknown 
reasons. He recovered completely while under infusion therapy 
FiGuRe 4 | Change of performance in executive function (epitrack®) as 
well as verbal (VlMt delayed free recall after 30 min) and figural 
(dCs-R learning performance across five trials) memory performance. 
Memory performance was standardized (standard values; mean = 100, 
SD = 10) according to a normative sample of 488 healthy volunteers who 
underwent both tests for co-normalization. Performance in executive function 
was standardized based on normative data of the EpiTrack® (689 healthy 
volunteers).
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and without the aid of dialysis. Since basiliximab is usually given 
during kidney transplantation and this side effect had not been 
previously described for basiliximab, it was assumed that the 
renal failure was not related to basiliximab. No other side effects 
occurred, besides a certain tiredness after the basiliximab infusion.
discussion and Concluding Remarks
Glutamate decarboxylase 65-ABs can also be found in other dis-
eases, such as stiff person syndrome or even type 1 diabetes mellitus. 
However, the ABs from these entities do not differ in their target 
regions (18). In more than 90% of all cases with GAD65-ABs, there 
are GAD65-ABs against linear epitopes, which are only “visible” 
in fractions of GAD65, perhaps after lysosomal deconstruction, 
but not in the intact enzyme (19). In type 1 diabetes mellitus, an 
attempt was made to achieve immune tolerance against GAD65 
by vaccinating with a GAD65 preparation. However, a phase 3 
study was aborted because no improvements were found (20). In 
type I diabetes mellitus, a T-lymphocytic destruction of β cells is 
assumed to be the pathophysiological correlate (21). These experi-
ences with GAD65-AB LE and other GAD65-AB-related diseases 
suggest that, in contrast to autoimmune encephalitis with ABs to 
neuronal surface antigens, additional factors may determine the 
type and course of GAD65-AB LE.
From other patients with a GAD-65-AB LE and with unilateral 
TLE who underwent amygdalohippocampectomy as epilepsy-
surgical treatment, we know that cytotoxic T-lymphocytes were 
found in histological preparations of temporomesial structures 
(7). Experimental studies have shown that an attack of cytotoxic 
T-lymphocytes against neurons could result in a perforin-
dependent electrical silencing, which is not necessarily linked to 
neuronal cell death (22). Thus, a chronic epilepsy by non-lethal 
cytotoxic attacks against GAD65 expressing GABAergic interneu-
rons is possible. An alternative explanation for the existence of 
similar GAD65-ABs in different diseases could be that primarily 
there is an attack by cytotoxic T-lymphocytes against, e.g., GAD65 
expressing GABAergic interneurons (or β-cells in type 1 diabetes 
mellitus) and second, partly denaturized GAD65 comes into 
contact with the humoral part of the immune system, resulting in 
the production of GAD65-ABs, also against linear epitopes of the 
enzyme, due to prior lysosomal denaturation. Therefore, a direct 
therapy against GAD65-ABs should fail, whereas an attenuated 
activation cytotoxic T-lymphocytes should be helpful.
The close correlation of the fraction of activated cytotoxic 
T-lymphocytes in CSF with clinical and paraclinical measures 
of disease activity in our case, together with the unambiguous 
response to basiliximab strongly argues in favor of a putative 
pathogenic role of cytotoxic T-cells in anti-GAD65 LE.
FiGuRe 5 | ethyl 8-fluoro-5-[(11)C]methyl-6-oxo-4H-imidazo[1,5-a][1,4]
benzodiazepine-3-carboxylate positron emission tomography 
(=11C-flumazenil Pet). (a) Scan before first application of basiliximab, 
normalized to injected activity of 580 MBq with an acquisition time from 20 to 
40 min after injection. (B) Scan after sixth application of basiliximab, normalized 
to injected activity 674 MBq with the same acquisition time from 20 to 40 min 
after injection. (C) Subtraction A–B, only positive results are displayed. A 
decrease of activity from A to B is clearly visible. (d) Subtraction B–A, only 
positive results are displayed. An increase of activity from A to B is hardly 
distinguishable from random noise.
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Overall, the treatment was not completely successful. The 
seizures became less severe during therapy, but seizure freedom 
was achieved only for a short time.
Neuropsychological tests did not show any definitive therapy-
related changes; only affective disturbances and impulsiveness 
improved at a clinical level. MRI-volumetry showed, at most, a 
trend toward normalization of swollen amygdalae. Amygdala 
swelling is frequently observed in patients with LE.
Impressive results can be seen in the CSF. Here, the fraction of 
activated T-lymphocytes was normalized under treatment and, 
later on, also the AB concentration was reduced. Furthermore, 
impressive changes in GABA metabolism as represented by the 
FiGuRe 6 | Magnetic resonance imaging-volumetry of hippocampus 
and amygdala (measured in cubic millimeter) corrected by the 
whole brain volume (measured in cubic centimeter) of each scan. 
The resulting values are unitless values measured as cubic millimeter per 
cubic centimeter. Before therapy, there is a fluctuation with more volume 
of right temporomesial structures. Last volumetry, acquired during the 
period without seizures shows a consensual volume-decrease in both 
amygdalae.
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flumazenil PET were observed. Unfortunately, only two PET 
scans exist because of problems related to radiation exposure. 
For the same reason, no control group of healthy persons was 
available as radioactive scans from healthy volunteers are difficult 
to obtain due to ethical reasons.
The clinical relapse at the end of the observation period might 
be caused by the formation of HADAs, a well-known complication 
of therapy with chimeric ABs (10, 11). Proving this hypothesis has 
not been possible up until now. The therapy, however, was discon-
tinued in order to avoid anaphylactic reactions and, as a result, 
the clinical situation was even more impaired. The patient did not 
agree to an alternative therapy with natalizumab because of the 
risk of progressive multifocal leukoencephalopathy. We are antici-
pating the approval of a new, homologous therapeutic AB, which 
has shown to be effective in the long-term therapy of multiple 
scleroses (8, 23). This new AB, daclizumab hyp, is hypoallergenic 
and was administered in monotherapy in much higher doses (150 
or 300 mg/month). The administered dose of 20 mg of basiliximab 
in this case was much lower. An increase might have been more 
effective, since the observed dramatic expansion of CD56 bright 
NK cells under Daclizumab hyp (23) could be observed here, but 
only a slight trend was visible (data not shown).
However, the dose of basiliximab was not increased as it has 
yet to be approved for administration at higher doses. On the 
other hand, the intervals of application could not be shortened 
since cortisone pulses are usually administered monthly. Because 
of security concerns, basiliximab was always given to the patient 
when he was on the ward during his in-hospital stay.
Based on this case report, a controlled study using a higher 
dose of daclizumab hyp for the therapy of GAD65-AB LE 
with increased fraction of cytotoxic T-lymphocytes in CSF 
might be reasonable.
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